GA-68-DOTATOC

GA-68-DOTATOC Uses, Dosage, Side Effects, Food Interaction and all others data.

GA-68-DOTATOC is an 8 amino acid peptide bound to the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). GA-68-DOTATOC is indicated for localizing somatostatin receptor positive neuroendocrine tumors by positron emission tomography. Dotatate gallium Ga-68 is used for a similar indication. Dotatate gallium Ga-68 has lower tumor uptake but this data is highly variable between patients.

GA-68-DOTATOC was granted FDA approval on 21 August 2019.

GA-68-DOTATOC binds to somatostatin receptors where it emits beta particle radiation for detection by positron emission tomography. The duration of action is short as it has short radioactive and biological half lives. Patients should hydrate before and after the administration of this medication to encourage frequent urination and rapid clearance.

GA-68-DOTATOC
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	GA-68-DOTATOC
Generic	Edotreotide gallium Ga-68
Edotreotide gallium Ga-68 Other Names	Edotreotide Gallium Ga-68, Gallium (68Ga) edotreotide, Gallium edotreotide Ga-68, Gallium Ga 68-dotatoc, Gallium Ga 68-edotreotide, Gallium Ga-68 edotreotide
Type	Injection, solution
Formula	C₆₅H₈₉GaN₁₄O₁₈S₂
Weight	Average: 1486.55 Monoisotopic: 1485.520052927
Protein binding	Data suggests edotreotide gallium-Ga 68 may bind to proteins in serum. The extent of serum protein binding and which proteins it binds to are not described in the literature.
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

GA-68-DOTATOC is a radioactive diagnostic agent used in PET scans for somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients.

GA-68-DOTATOC is a radioactive diagnostic compound used in positron emission tomography (PET) for diagnose somatostatin receptor positive neuroendocrine tumors in pediatrics and adults.

GA-68-DOTATOC is also used to associated treatment for these conditions: Neuroendocrine Tumors

How GA-68-DOTATOC works

GA-68-DOTATOC binds to somatostatin receptors, with higher affinity for somatostatin receptor type 2, where it emits beta particle radiation for detection by positron emission tomography (PET).

Toxicity

The LD₅₀ of this medication is not readily available.

In the event of an overdose, give patients plenty of fluids and diuretics if necessary to encourage frequent urination. If possible, an estimation of radioactive dose should be performed.

Food Interaction

No interactions found.

Volume of Distribution

Data regarding the volume of distribution of this medication is not readily available.

Elimination Route

GA-68-DOTATOC reaches 80% activity in tumors within 30 minutes, and reaches its highest activity in tumors 70±20min post injection. Edotreotide is mostly taken up into the spleen, followed by kidneys, liver, pituitary, thyroid, and adrenal gland. Accumulation in non-tumor tissue reaches a maximum within 40 minutes.

Half Life

GA-68-DOTATOC has a radioactive half life of 68 minutes. GA-68-DOTATOC has two half lives, 2.0±0.3min and 48±7min for its removal from blood.

Clearance

Data regarding the clearance of this medication is not readily available.

Elimination Route

16% of a GA-68-DOTATOC dose is eliminated in the urine within 2h. It is expected that GA-68-DOTATOC is exclusively eliminated in the urine. In animal studies, edotreotide Y-90 was >80% eliminated in the urine within 24h, with 95.6±3.4% being unmetabolized. 5